Overview
- Researchers reviewing randomized trials and real‑world analyses report that starting metformin during or shortly after SARS‑CoV‑2 infection is associated with fewer long COVID diagnoses.
- COVID‑OUT found a 41% relative reduction in long COVID over 10 months, rising to 63% when begun within three days of symptom onset, with observed decreases in viral load and rebound.
- ACTIV‑6 reported about a 50% lower risk of clinician‑diagnosed long COVID with metformin, though the estimate carried uncertainty.
- Trials used a 500 mg dose escalated over 14 days for roughly 36 total doses, with no serious adverse events or hypoglycemia reported and minimal gastrointestinal issues.
- Authors note potential public‑health impact from a low‑cost drug that may prevent roughly one long‑COVID case per 50 treated, while emphasizing trial limits and the need for broader confirmation before routine use.